December 19, 2022

RF Medical’s Mygen M-3004 and Myoblate Radiofrequency Ablation System Cleared by FDA

December 19, 2022—RF Medical Co., Ltd., a Korea-based manufacturer of thermal ablation systems, recently announced FDA clearance of the company’s Mygen M-3004 generator and Myoblate radiofrequency ablation system, which are now commercially available in the United States.

According to the company, the Mygen M-3004 enables a combination of monopolar and bipolar modes. In addition to delivering radiofrequency energy more effectively, it supports optimized algorithm modes for use in a variety of lesions depending on their size and shape.

The Myoblate system’s electrodes are intended for soft tissue coagulation and ablation to treat uterine fibroids, providing a less-invasive and more patient-friendly alternative to hysteroscopy or myomectomy, stated the company.

Subscribe to our weekly newsletter.

Stay informed on the week's top stories including literature summaries, device approvals, guideline changes, and more. Plus, get our latest issues & supplements delivered to your inbox each month.

December 19, 2022

RF Medical’s Mygen M-3004 and Myoblate Radiofrequency Ablation System Cleared by FDA

Current Issue

Keep In Touch